Editas Medicine Inc expected to post a loss of 36 cents a share - Earnings Preview

Editas Medicine

03/03/2025 13:38

Editas Medicine Inc EDIT.OQ EDIT.O is expected to show a fall in quarterly revenue when it reports  results on March 5 for the period ending December 31 2024

The Cambridge Massachusetts-based  company is expected to report a 46.3% decrease in revenue to $32.23 million from $60.05 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Editas Medicine Inc is for a loss of 36 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 9 "hold" and 2 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Editas Medicine Inc is $3.50​, above​ its last closing price of $1.92. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.72
-0.75
-0.75
Met
-0.4
Jun. 30 2024
-0.73
-0.70
-0.82
Missed
-16.6
Mar. 31 2024
-0.66
-0.66
-0.76
Missed
-14.3​
Dec. 31 2023
-0.60
-0.54
-0.23
Beat
57.6
​​Sep. 30 2023
-0.56
-0.57
-0.55
Beat
3.2
Jun. 30 2023
-0.76
-0.76
-0.56
Beat
26.6​
Mar. 31 2023
-0.78
-0.78
-0.71
Beat
9.4
Dec. 31 2022
-0.80
-0.80
-0.88
Missed
-9.7

This summary was machine generated March 3 at 13:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)